AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesHealth Care
Wet Macular DegenerationMacular DegenerationChoroidal NeovascularizationRetinal DrusenRetinal Pigment EpitheliumRetinal DegenerationGeographic AtrophyFluorescein AngiographyChoroidVisual AcuityNerve DegenerationComplement Factor HBruch MembranePigment Epithelium of EyeIntravitreal InjectionsRetinaMacula LuteaLipofuscinOptic Disk DrusenFundus OculiWallerian DegenerationTomography, Optical CoherenceChoroid DiseasesLuteinFovea CentralisPhotoreceptor Cells, VertebrateAngiogenesis InhibitorsRetinal NeovascularizationElectroretinographyExudates and TransudatesPhotochemotherapyEye ProteinsIntervertebral Disc DegenerationOphthalmoscopyXanthophyllsSubretinal FluidPhotographyScotomaRetinal DiseasesAgingAntibodies, Monoclonal, HumanizedEye DiseasesRetinal DetachmentRetinal HemorrhageVision DisordersVision, LowComplement Factor BIndocyanine GreenPolymorphism, Single NucleotideLaser CoagulationGenotypeDisease Models, AnimalBlindnessVision TestsVascular Endothelial Growth Factor AComplement C2Retinitis PigmentosaEye Diseases, HereditaryPhotosensitizing AgentsFrontotemporal Lobar DegenerationCataractRetinoidsRetinal PigmentsPorphyrinsAtrophyLight CoagulationRetinal Photoreceptor Cell Outer SegmentGenetic Predisposition to DiseaseEye BanksEye ColorVitreous BodyCase-Control StudiesInjections, IntraocularPyridinium CompoundsVisual Field TestsDiagnostic Techniques, OphthalmologicalEye
RanibizumabEYLEAAvastinNeovascularRisk of macular degenerationOcclusionBevacizumabFamily history of macular degenerationRetinaAfliberceptMaculaOedemaTypes of macularVEGFTreatmentsWAMDChoroidalInjectionInjectionsRetinopathyTreatmentBlood vesselsVascularDosePatientsGenentech2021Clinical trialsDiagnosisVabysmoAffectsSignsBlindnessBrolucizumabGene therapyDiseaseTherapiesVisionVitreousMedicationInclude
Ranibizumab16
  • Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110 . (pharmfair.com)
  • His discoveries led to the development of ranibizumab (trade name Lucentis ® ), a treatment that can help halt and even reverse vision loss in the many patients who experience severe vision loss or blindness caused by the wet form of age-related macular degeneration (AMD). (jnj.com)
  • Lucentis (ranibizumab) Injection is a monoclonal antibody that works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels used to treat the wet form of age-related macular degeneration. (quizbuzzers.nl)
  • At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health. (blogspot.com)
  • Lucentis (Ranibizumab) , manufactured by Genentech, was approved to treat wAMD in June 2006. (remedy-one.com)
  • This is a Phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of three different formulations of ranibizumab delivered via the Ranibizumab Port Delivery System (RPDS) implant compared with the standard of care (SOC) intravitreal (ITV) injections of ranibizumab, in participants with subfoveal neovascular age-related macular degeneration (AMD). (californiaretina.com)
  • The main anti-VEGF therapies in current use are bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (Eylea). (biomedcentral.com)
  • Three drugs, which all inhibit the neovascularisation process in blocking the Vascular Epithelial Growth Factor (VEGF) pathway have been approved worldwide: Avastin or bevacizumab (Roche-Genentech), Lucentis or ranibizumab (Novartis) and Eylea or aflibercept (Bayer and Regeneron). (btobioinnovation.com)
  • Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. (citeline.com)
  • Final guidance from NICE, published 29 June 2022, approved faricimab as a treatment option for adults with nAMD or DMO if it is used in the same population as aflibercept (Eylea, Bayer) and ranibizumab (Lucentis, Novartis) [2,3]. (uk.com)
  • The study eye had not yet received treatment for active choroidal neovascularization, and patients received either ranibizumab ( Lucentis , Genentech) or bevacizumab ( Avastin , Genentech) in one of three dosing regimens. (medscape.com)
  • Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (jamanetwork.com)
  • Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. (jamanetwork.com)
  • Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. (jamanetwork.com)
  • Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. (jamanetwork.com)
  • Susvimo (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor. (rxlist.com)
EYLEA8
  • EYLEA is a prescription medicine that has been approved by the FDA for the treatment of patients with wet AMD. (vmrinstitute.com)
  • Intraocular injections of Avastin, Lucentis, and Eylea are often successful in stopping abnormal blood vessel growth in wet macular degeneration. (sdesign.studio)
  • With sales hitting $5.21 Billion in 2021, Eylea competed primarily with Lucentis, which is usually dosed every 4 weeks, and quickly surpassed Lucentis as the market leader in the AMD/Diabetic Eye Disease category. (remedy-one.com)
  • For many years Lucentis, Eylea, and off-label use of Avastin (which will be discussed later) were the mainstays for anti-VEGF treatment. (remedy-one.com)
  • Avastin, at approximately $50 per average treatment, is significantly less expensive for the patient than the alternatives (~$1,800 for Eylea and ~$2,000 for Lucentis). (city-data.com)
  • The main treatment drugs for exudative age-related macular degeneration are Eylea, Lucentis, and Avastin alongside some novel drugs such as Vabysmo and Beovu. (optometrytimes.com)
  • Eylea and Lucentis cost about $1800 per dose whereas Vabysmo costs $2,190 per treatment. (optometrytimes.com)
  • The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold? (evaluate.com)
Avastin6
  • Avastin and Lucentis block growth of abnormal blood vessels and leakage of fluid from the vessels. (blogspot.com)
  • Avastin is very similar to Lucentis but is not approved by the FDA for this purpose. (blogspot.com)
  • Thus, CATT was designed to compare Avastin and Lucentis with monthly and as-needed treatment schedules. (blogspot.com)
  • At enrollment, patients were assigned to four treatment groups defined by drug (Avastin or Lucentis) and dosing regimen (monthly or as-needed). (blogspot.com)
  • Even with the monthly eye shots of avastin the macular degeneration is now advancing to the point i'm having trouble reading. (city-data.com)
  • Weekly sounds a bit extreme, the shots consist of a drug called Avastin that is injected into the eye to curb the bleeding of the eyes macular lining, not sure i'd call myself lucky to have to undergo this treatment for the rest of my life. (city-data.com)
Neovascular14
  • Indicated for neovascular (wet) age-related macular degeneration (ARMD). (medscape.com)
  • Macular degeneration can be classified as either wet (neovascular) or dry (non-neovascular). (sdesign.studio)
  • Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). (secunderabadchronicle.in)
  • VEGF inhibitors reduce leakage from blood vessels, prevent formation of new abnormal vessels, decrease swelling in the retina, and improve visual acuity in patients with neovascular (wet) AMD, Diabetic Retinopathy, and Diabetic Macular Edema. (remedy-one.com)
  • The overall objective of this study is to evaluate the molecular concentration of growth factors, cytokines and chemokines in human aqueous humor and vitreous samples collected from individuals undergoing pars plana vitrectomy for tractional retinal detachment secondary to proliferative diabetic retinopathy, exudative or tractional retinal detachment secondary to macular degeneration, macular hole or neovascular glaucoma. (californiaretina.com)
  • As background, Beovu was approved by the FDA in 2019 as a treatment for neovascular (wet) age-related macular degeneration (AMD). (druginjurylaw.com)
  • In the wet, or exudative, form of age-related macular degeneration (AMD or ARMD), pathologic choroidal neovascular membranes (CNVM) develop under the retina. (medscape.com)
  • An atrophic or "dry" form which progresses slowly and destroys the central vision and the "wet" form where new vessels are formed in the choroid and/or retina, the neovascular form. (btobioinnovation.com)
  • Branded Byooviz, it is also the first biosimilar to be approved for ophthalmology indications - neovascular (wet) age-related macular degeneration (AMD), macular edema, retinal vein occlusion, and myopic choroidal neovascularization. (sathguru.com)
  • Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration ( nAMD ) and diabetic macular oedema ( DMO ) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor ( anti-VEGF ) therapies, including regulatory positions on biosimilar products. (uk.com)
  • Patients with neovascular age-related macular degeneration (AMD) who have a poor initial response to an antivascular endothelial growth factor (anti-VEGF) agent may still respond to treatment with the same drug over time, without being switched to an alternative agent, the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) study suggests. (medscape.com)
  • Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. (jamanetwork.com)
  • Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. (jamanetwork.com)
  • Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (jamanetwork.com)
Risk of macular degeneration4
Occlusion6
  • It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. (pharmfair.com)
  • For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. (pharmfair.com)
  • LUCENTIS is the first FDA-approved medicine to treat wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and the 2 forms of macular edema following retinal vein occlusion (RVO): branch RVO (BRVO) and central RVO (CRVO). (vmrinstitute.com)
  • Lucentis later gained FDA approval to treat diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (ME after RVO), and myopic choroidal neovascularization (mCNV). (remedy-one.com)
  • Retinal diseases, which are often characterized by leakage of fluid, hemorrhage and fibrous scarring in the eye, include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and choroidal neovascularization (CNV) not secondary to AMD. (biomedcentral.com)
  • Bevacizumab was demonstrated in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to aflibercept with respect to visual acuity in study participants with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) following 6 months of therapy. (bvsalud.org)
Bevacizumab3
  • Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group. (jamanetwork.com)
  • Objective: To investigate the relative cost-effectiveness of bevacizumab vs aflibercept for treatment of macular edema associated with CRVO or HRVO. (bvsalud.org)
  • Conclusions and Relevance: While there will be some patients with CRVO-associated or HRVO-associated macular edema who will benefit from first-line treatment with aflibercept rather than bevacizumab, given the minimal differences in visual acuity outcomes and large cost differences for bevacizumab vs aflibercept, first-line treatment with bevacizumab is cost-effective for this condition. (bvsalud.org)
Family history of macular degeneration2
Retina9
  • Sutureless microsurgery is an area of expertise at the VMR Institute for Vitreous Macular Retina. (vmrinstitute.com)
  • Macular degeneration affects the macula, the part of the retina responsible for the crisp, detailed vision needed for reading or driving. (sdesign.studio)
  • In wet macular degeneration, new blood vessels develop beneath the retina and cause a leakage of blood and fluid. (sdesign.studio)
  • Macular degeneration (specifically the "wet" type) is an eye condition that is directly caused by abnormal blood vessel growth, which starts in the choroid and go through the Bruchs Membrane to the retina (known as choroidal neovascularization). (qldblind.org.au)
  • Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina and would fall into the latter category. (remedy-one.com)
  • As you get older, the macula, which is responsible for central vision, can deteriorate, leading to macular degeneration of the retina. (sightconnection.org)
  • AMD is characterized by a progressive degeneration of the central zone of the retina: the macula. (btobioinnovation.com)
  • La mácula es una pequeña región en el centro de la retina que es rica en conos, los fotorreceptores que permiten a una persona percibir detalles finos (por ejemplo, leer o reconocer rostros), colores, y objetos durante el día o en condiciones con buena iluminación. (fightingblindness.org)
  • Dr. Randy Katz, Florida Eye's Vitreo-Retina, Diabetic Retinopathy, Retinal Detachment & Macular Degeneration Specialist is thrilled about the positive results he's been seeing during trials with a new anti-PDGF drug which compares Lucentis with anti-PDGF medication to just Lucentis. (fleyedocs.com)
Aflibercept2
  • The high-dose version comprises 8mg of Eylea's active ingredient, aflibercept, in a novel formulation, which the groups hope could be dosed as infrequently as every 16 weeks. (evaluate.com)
  • Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (jamanetwork.com)
Macula6
  • Lucentis works on those chemicals, so your body produces fewer damaged vessels behind your macula. (nvisioncenters.com)
  • This type of disease usually develops as a result of aging and thinning of macular tissues and the depositing of pigment within the macula. (sdesign.studio)
  • Around the macular area, visual cells are not as closely packed as in the macula itself, but they are good enough for our peripheral vision to work properly. (qldblind.org.au)
  • In its advanced stages, the wet form of AMD spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. (blogspot.com)
  • It is characterized by the degeneration of the macula, which is responsible for fine detail vision. (sightconnection.org)
  • The harmful chemicals in cigarette smoke can damage the blood vessels in the eyes and decrease the flow of oxygen to the macula, increasing the risk of macular pathology. (sightconnection.org)
Oedema1
Types of macular2
  • Physicians have traditionally recognized 2 types of macular degeneration: dry and wet. (medscape.com)
  • There are two types of macular degeneration-wet and dry. (networkofcare.org)
VEGF2
  • Lucentis is an anti-VEGF medication. (nvisioncenters.com)
  • There are two types of injections for medications that inhibit vascular growth anti-VEGF - three drugs of this type approved for treatment abstain, ilia, Lucentis. (mondovebiotech.com)
Treatments4
  • All treatments for wet macular degeneration are administered by an in office procedure called an intravitreal injection. (eyeknowmore.com)
  • He has served as an investigator/sub-investigator in numerous studies of new retinal treatments, including being a principal investigator for the landmark Lucentis® treatment for wet age-related macular degeneration. (rgw.com)
  • By 2030, it is predicted that the global market for age-related macular degeneration treatments will be around $18 billion. (optometrytimes.com)
  • Drs. Lee Friedman and Randy Katz of Florida Eye shared the latest updates on Retinopathy of Prematurity & Its Complications & Macular Degeneration & Retinal Vascular Disease Treatments, respectively. (fleyedocs.com)
WAMD2
  • This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD). (secunderabadchronicle.in)
  • wet AMD (wAMD) is less common but too often results in more serious loss of vision. (remedy-one.com)
Choroidal3
Injection4
  • LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65MG/0.165ML is approved to be sold in Singapore with effective from 2015-10-04 . (pharmfair.com)
  • The recommended dose for Lucentis in adults is 0.5 mg given as a single intravitreal injection. (medicines.org.uk)
  • For age-related macular degeneration it is given by injection into the eye (intravitreal). (wikipedia.org)
  • It is recommended not to wet the eye a few days after injection. (mondovebiotech.com)
Injections3
Retinopathy2
Treatment18
  • Lucentis is FDA approved for the treatment of wet AMD. (eyeknowmore.com)
  • The goal of treatment in wet AMD is three fold: maximize vision in the affected eye, prevent the development of wet AMD in the other eye, and early detection of wet AMD in the other eye should it occur. (eyeknowmore.com)
  • Gass J, Donald M. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment . (medscape.com)
  • During a Lucentis treatment, your doctor numbs your eye and props it open (so a blink can't ruin the procedure). (nvisioncenters.com)
  • In two well-controlled clinical studies of over 2400 patients with wet AMD this treatment frequency was shown to maintain* or improve vision over one year in more than 9 out of 10 patients. (vmrinstitute.com)
  • While there is no cure for macular degeneration, there are several treatment options available to help patients manage this condition and preserve their vision. (sdesign.studio)
  • It is essential for patients with macular degeneration, wet or dry, to seek continuous medical treatment to manage their condition and prevent permanent vision loss from occurring. (sdesign.studio)
  • If, in the physician's opinion, visual and anatomic parameters indicate that the patient is not benefiting from continued treatment, Lucentis should be discontinued. (medicines.org.uk)
  • The treatment interval should be extended by no more than two weeks at a time for wet AMD and may be extended by up to one month at a time for DME. (medicines.org.uk)
  • Lucentis was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of AMD. (blogspot.com)
  • Patients in Japan stand to benefit from the approval of four innovative medicines - Tasigna® for the treatment of a life-threatening form of leukemia, Xolair® for severe asthma, Co-Dio®[*] for high blood pressure, and Lucentis® for wet age-related macular degeneration (AMD), an eye disease that is a major cause of blindness in people over the age of 50 in Japan. (worldpharmanews.com)
  • DelveInsight's Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Wet Age-Related Macular Degeneration treatment. (secunderabadchronicle.in)
  • For each data source, availability and quantity of data on baseline status, clinical outcomes, treatment and management, safety, and patient-reported and economic burden were assessed using a bespoke completeness assessment tool based on International Consortium for Health Outcomes Measurement guidelines for macular degeneration. (biomedcentral.com)
  • If you experience any of these signs and symptoms of age-related macular degeneration, it is crucial to seek medical attention for proper diagnosis and treatment. (sightconnection.org)
  • Treatment for wet AMD can sometimes delay further damage to your central vision . (networkofcare.org)
  • The main treatment for wet AMD is a medicine that is injected into your eye. (networkofcare.org)
  • Because wet AMD often causes rapid and severe loss of central vision, it is important not to delay treatment if your doctor recommends it. (networkofcare.org)
  • A potential patient must be newly diagnosed with wet macular degeneration and have had no previous treatment for the condition. (fleyedocs.com)
Blood vessels4
Vascular1
Dose2
  • The cost per dose of Lucentis 0.5mg is $1,950 and 0.3mg is $1,170. (remedy-one.com)
  • Another study that compares Lucentis with high dose Lucentis for the study eye as well as the non study eye is also underway at Florida Eye. (fleyedocs.com)
Patients11
Genentech1
  • Prior to joining the company, Khurem was the Senior Vice President of the Immunology and Ophthalmology business unit at Genentech and responsible for managing the commercial success of Lucentis and the pre-launch activities for lampalizumab for age-related macular degeneration. (gyroscopetx.com)
20211
  • Sales for Lucentis in 2021 totaled $2.28 Billion and accounted for one-fourth of the market share. (remedy-one.com)
Clinical trials1
  • However, in the original clinical trials for AMD, Lucentis was administered monthly. (blogspot.com)
Diagnosis1
Vabysmo2
  • In these studies, nearly 80% of people receiving Vabysmo for wet AMD could be treated every 3 months or longer, while more than 60% could be treated every four months. (optometrytimes.com)
  • Roche recently got approval for a new wet age-related macular degeneration drug, Vabysmo , but Regeneron and Bayer are not ready to give up their crown. (evaluate.com)
Affects4
Signs2
Blindness3
Brolucizumab1
  • Beovu (brolucizumab) Novartis' own successor of Lucentis has been approved in 70 countries, including the US, EU, UK, Japan and Australia, but a recent study showed unexpected high degrees of vasculitis and ocular venous occlusions. (btobioinnovation.com)
Gene therapy1
  • The Company was founded to capitalise on a convergence of advancements made in the understanding of the complement system's impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of sustained drug delivery. (gyroscopetx.com)
Disease6
  • This disease can also be related to a genetic factor in a patient who have a gene variant known as complement factor H. Nearly half of the blinding cases of macular degeneration are linked to this genetic deficiency. (sdesign.studio)
  • A common eye disease amongst the elderly is age-related macular degeneration (AMD). (qldblind.org.au)
  • Most clinicians use these drugs on an as-needed basis when there is evidence of active disease, such as fluid leakage. (blogspot.com)
  • There are two forms of the disease-dry AMD and wet AMD. (pinnaclecare.com)
  • Wet AMD is the more severe form of the disease. (pinnaclecare.com)
  • Since 2006, anti-angiogenic agents, which had first been developed to treat various cancers, have drastically changed the outcome of the "wet" form of disease. (btobioinnovation.com)
Therapies1
Vision9
  • Wet AMD comes in a spectrum from those who have driving level vision upon being diagnosed to others who are legally blind. (eyeknowmore.com)
  • With wet macular degeneration, central vision loss can occur rapidly. (sdesign.studio)
  • Regular eye exams are important in detecting macular degeneration and other serious eye conditions as early as possible, so that the risk of permanent vision loss can be minimized. (sdesign.studio)
  • As the U.S. population ages, the number of people living with age-related macular degeneration (AMD), a leading cause of vision loss in people 55 and older, has grown substantially. (pinnaclecare.com)
  • On the other hand, wet AMD is less common but leads to more severe vision loss. (sightconnection.org)
  • Wet AMD is already at an advanced stage and can progress rapidly, leading to significant and rapid loss of central vision. (sightconnection.org)
  • Age Related Macular Degeneration (AMD) is the major cause of irreversible central vision loss. (btobioinnovation.com)
  • Macular degeneration makes it harder to do things that require sharp central vision, like reading, driving, and recognizing faces. (networkofcare.org)
  • The initial trial results show that 60% gained 3 or more lines of vision compared to 40% for Lucentis alone," says Dr. Katz. (fleyedocs.com)
Vitreous1
Medication3
  • Lucentis is not the only medication available to treat wet AMD. (nvisioncenters.com)
  • In clinical trial news, we are very happy to report continuing positive results for Dr. Katz's clinical trial studies with the new anti-PDGF drug by Ophthotech, which compares Lucentis with anti-PDGF medication to just Lucentis. (fleyedocs.com)
  • Sal* has been receiving the medication Lucentis for the past eight months, and has gone from being "almost blind" to seeing "the textures of walls and individual blades of grass. (fleyedocs.com)
Include1
  • Common side effects of Lucentis include: discomfort and increased tears in the affected … In your question, you mentioned that you are experiencing anxiety and insomnia after stopping. (quizbuzzers.nl)